Taken together these data suggest that taxane resistance in endometrial cancer cells involves upregulated PI3K/AKT/mTOR pathway activity, however this increase does not reduce – but rather potentially increases – sensitivity to sapanisertib plus serabelisib. The gene discussed is MTOR; the disease is endometrial cancer.